. Author manuscript; available in PMC: 2021 Feb 1.

Published in final edited form as: Am J Obstet Gynecol MFM. 2019 Dec 17;2(1):100077. doi: 10.1016/j.ajogmf.2019.100077

Table 2.

Neonatal outcomes by timing of antenatal corticosteroid administration

	<2 days (n=622)	2 to <7 days (n=821)	7 to <14 days (n=401)	≥ 14 days (n=415)	p-value
Male neonate	331 (53.2)	434 (52.9)	214 (53.4)	248 (59.8)	0.11
Birthweight (mean grams, ± SD)	1486 ± 550	1296 ± 475	1310 ± 458	1585 ± 469	<0.001
Respiratory distress syndrome	390 (62.7)	421 (51.3)	224 (55.9)	239 (57.6)	<0.001
Neonatal severe morbidity^*	146 (23.5)	253 (30.8)	124 (30.9)	93 (22.4)	0.001
Neonatal death	41 (6.6)	59 (7.2)	31 (7.7)	21 (5.1)	0.43
Intraventricular hemorrhage grade III / IV	42 (6.8)	20 (2.4)	11 (2.7)	11 (2.7)	<0.001
Periventricular leukomalacia	14 (2.2)	17 (2.1)	8 (2.0)	9 (2.2)	0.99
Bronchopulmonary dysplasia	67 (10.8)	146 (17.9)	67 (16.8)	41 (10.0)	<0.001
Necrotizing enterocolitis	31 (5.0)	80 (9.8)	45 (11.3)	33 (8.0)	0.001
Childhood morbidity^†	65/610 (10.7)	29/262 (11.1)	33/316 (10.4)	26/323 (8.1)	0.570

Data presented as n (%) or mean +/− standard deviation

Composite included death, severe intraventricular hemorrhage grade III or IV, periventricular leukomalacia, bronchopulmonary dysplasia, or necrotizing enterocolitis

^†

Composite included death or moderate to severe cerebral palsy at age 2 among the 1511 women included in this analysis who were originally enrolled in the BEAM study and had longer-term follow-up data available